Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Deciphering Multifactorial Resistance Phenotypes in Acinetobacter baumannii by Genomics and Targeted Label-free Proteomics.

Cecchini T, Yoon EJ, Charretier Y, Bardet C, Beaulieu C, Lacoux X, Docquier JD, Lemoine J, Courvalin P, Grillot-Courvalin C, Charrier JP.

Mol Cell Proteomics. 2018 Mar;17(3):442-456. doi: 10.1074/mcp.RA117.000107. Epub 2017 Dec 19.

2.

New aminoglycoside-modifying enzymes APH(3')-VIII and APH(3')-IX in Acinetobacter rudis and Acinetobacter gerneri.

Yoon EJ, Grillot-Courvalin C, Courvalin P.

J Antibiot (Tokyo). 2017 Apr;70(4):400-403. doi: 10.1038/ja.2016.144. Epub 2016 Dec 14.

PMID:
27965516
3.

Contribution of the Ade Resistance-Nodulation-Cell Division-Type Efflux Pumps to Fitness and Pathogenesis of Acinetobacter baumannii.

Yoon EJ, Balloy V, Fiette L, Chignard M, Courvalin P, Grillot-Courvalin C.

MBio. 2016 May 31;7(3). pii: e00697-16. doi: 10.1128/mBio.00697-16.

4.

Origin in Acinetobacter gyllenbergii and dissemination of aminoglycoside-modifying enzyme AAC(6')-Ih.

Yoon EJ, Goussard S, Nemec A, Lambert T, Courvalin P, Grillot-Courvalin C.

J Antimicrob Chemother. 2016 Mar;71(3):601-6. doi: 10.1093/jac/dkv390. Epub 2015 Dec 7.

5.

Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in Acinetobacter baumannii.

Yoon EJ, Chabane YN, Goussard S, Snesrud E, Courvalin P, Dé E, Grillot-Courvalin C.

MBio. 2015 Mar 24;6(2). pii: e00309-15. doi: 10.1128/mBio.00309-15.

6.

Origin in Acinetobacter guillouiae and dissemination of the aminoglycoside-modifying enzyme Aph(3')-VI.

Yoon EJ, Goussard S, Touchon M, Krizova L, Cerqueira G, Murphy C, Lambert T, Grillot-Courvalin C, Nemec A, Courvalin P.

MBio. 2014 Oct 21;5(5):e01972-14. doi: 10.1128/mBio.01972-14.

7.

The genomic diversification of the whole Acinetobacter genus: origins, mechanisms, and consequences.

Touchon M, Cury J, Yoon EJ, Krizova L, Cerqueira GC, Murphy C, Feldgarden M, Wortman J, Clermont D, Lambert T, Grillot-Courvalin C, Nemec A, Courvalin P, Rocha EP.

Genome Biol Evol. 2014 Oct 13;6(10):2866-82. doi: 10.1093/gbe/evu225.

8.

Homologous prime boosting based on intranasal delivery of non-pathogenic invasive Escherichia coli expressing MPT64, decreases Mycobacterium tuberculosis dissemination.

Sali M, Dainese E, Morandi M, Zumbo A, Rocca S, Goussard S, Palù G, Grillot-Courvalin C, Delogu G, Manganelli R.

Vaccine. 2014 Jul 7;32(32):4051-8. doi: 10.1016/j.vaccine.2014.05.060. Epub 2014 Jun 2.

PMID:
24886957
9.

Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure.

McGann P, Courvalin P, Snesrud E, Clifford RJ, Yoon EJ, Onmus-Leone F, Ong AC, Kwak YI, Grillot-Courvalin C, Lesho E, Waterman PE.

MBio. 2014 Apr 22;5(2):e00915. doi: 10.1128/mBio.00915-14.

10.

Aminoglycoside resistance 16S rRNA methyltransferases block endogenous methylation, affect translation efficiency and fitness of the host.

Lioy VS, Goussard S, Guerineau V, Yoon EJ, Courvalin P, Galimand M, Grillot-Courvalin C.

RNA. 2014 Mar;20(3):382-91. doi: 10.1261/rna.042572.113. Epub 2014 Jan 7.

11.

Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections.

Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE.

J Infect Dis. 2013 Oct 1;208(7):1142-51. doi: 10.1093/infdis/jit293. Epub 2013 Jun 28.

PMID:
23812239
12.

RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations.

Yoon EJ, Courvalin P, Grillot-Courvalin C.

Antimicrob Agents Chemother. 2013 Jul;57(7):2989-95. doi: 10.1128/AAC.02556-12. Epub 2013 Apr 15.

13.

Bacterial delivery of large intact genomic-DNA-containing BACs into mammalian cells.

Cheung W, Kotzamanis G, Abdulrazzak H, Goussard S, Kaname T, Kotsinas A, Gorgoulis VG, Grillot-Courvalin C, Huxley C.

Bioeng Bugs. 2012 Mar-Apr;3(2):86-92. doi: 10.4161/bbug.18621. Epub 2012 Mar 1.

14.

Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci.

Foucault ML, Depardieu F, Courvalin P, Grillot-Courvalin C.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16964-9. doi: 10.1073/pnas.1006855107. Epub 2010 Sep 10.

15.

In vivo bioluminescence imaging for the study of intestinal colonization by Escherichia coli in mice.

Foucault ML, Thomas L, Goussard S, Branchini BR, Grillot-Courvalin C.

Appl Environ Microbiol. 2010 Jan;76(1):264-74. doi: 10.1128/AEM.01686-09. Epub 2009 Oct 30.

16.

Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus.

Foucault ML, Courvalin P, Grillot-Courvalin C.

Antimicrob Agents Chemother. 2009 Jun;53(6):2354-9. doi: 10.1128/AAC.01702-08. Epub 2009 Mar 30.

17.

CFTR expression from a BAC carrying the complete human gene and associated regulatory elements.

Kotzamanis G, Abdulrazzak H, Gifford-Garner J, Haussecker PL, Cheung W, Grillot-Courvalin C, Harris A, Kittas C, Kotsinas A, Gorgoulis VG, Huxley C.

J Cell Mol Med. 2009 Sep;13(9A):2938-48. doi: 10.1111/j.1582-4934.2008.00433.x. Epub 2008 Jul 24.

18.

Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli.

Brun P, Zumbo A, Castagliuolo I, Delogu G, Manfrin F, Sali M, Fadda G, Grillot-Courvalin C, Palù G, Manganelli R.

Vaccine. 2008 Apr 7;26(16):1934-41. doi: 10.1016/j.vaccine.2008.02.023. Epub 2008 Feb 25.

PMID:
18342411
19.

Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli.

Larsen MD, Griesenbach U, Goussard S, Gruenert DC, Geddes DM, Scheule RK, Cheng SH, Courvalin P, Grillot-Courvalin C, Alton EW.

Gene Ther. 2008 Mar;15(6):434-42. doi: 10.1038/sj.gt.3303090. Epub 2008 Jan 24.

20.

Factor VIII mRNA expression from a BAC carrying the intact locus made by homologous recombination.

Pérez-Luz S, Abdulrazzak H, Grillot-Courvalin C, Huxley C.

Genomics. 2007 Nov;90(5):610-9. Epub 2007 Sep 5.

21.

Bacterial transfer of large functional genomic DNA into human cells.

Laner A, Goussard S, Ramalho AS, Schwarz T, Amaral MD, Courvalin P, Schindelhauer D, Grillot-Courvalin C.

Gene Ther. 2005 Nov;12(21):1559-72.

PMID:
15973438
22.

Engineered E. coli delivers therapeutic genes to the colonic mucosa.

Castagliuolo I, Beggiao E, Brun P, Barzon L, Goussard S, Manganelli R, Grillot-Courvalin C, Palù G.

Gene Ther. 2005 Jul;12(13):1070-8. Erratum in: Gene Ther. 2005 Jul;12(14):1158.

PMID:
15815705
23.

Bacterial and host factors implicated in nasal carriage of methicillin-resistant Staphylococcus aureus in mice.

González-Zorn B, Senna JP, Fiette L, Shorte S, Testard A, Chignard M, Courvalin P, Grillot-Courvalin C.

Infect Immun. 2005 Mar;73(3):1847-51.

24.

Recombinant Escherichia coli as a gene delivery vector into airway epithelial cells.

Fajac I, Grosse S, Collombet JM, Thevenot G, Goussard S, Danel C, Grillot-Courvalin C.

J Control Release. 2004 Jun 18;97(2):371-81.

PMID:
15196763
25.

Eukaryotic promoters can direct protein synthesis in Gram-negative bacteria.

Goussard S, Grillot-Courvalin C, Courvalin P.

J Mol Microbiol Biotechnol. 2003;6(3-4):211-8.

PMID:
15153774
26.

Potential therapeutic applications of recombinant, invasive E. coli.

Critchley RJ, Jezzard S, Radford KJ, Goussard S, Lemoine NR, Grillot-Courvalin C, Vassaux G.

Gene Ther. 2004 Aug;11(15):1224-33.

PMID:
15141160
27.

Wild-type intracellular bacteria deliver DNA into mammalian cells.

Grillot-Courvalin C, Goussard S, Courvalin P.

Cell Microbiol. 2002 Mar;4(3):177-86.

PMID:
11906454
28.

Bacteria as gene delivery vectors for mammalian cells.

Grillot-Courvalin C, Goussard S, Courvalin P.

Curr Opin Biotechnol. 1999 Oct;10(5):477-81. Review. No abstract available.

PMID:
10508638
29.

Functional gene transfer from intracellular bacteria to mammalian cells.

Grillot-Courvalin C, Goussard S, Huetz F, Ojcius DM, Courvalin P.

Nat Biotechnol. 1998 Sep;16(9):862-6.

PMID:
9743121
30.

Gene transfer from bacteria to mammalian cells.

Courvalin P, Goussard S, Grillot-Courvalin C.

C R Acad Sci III. 1995 Dec;318(12):1207-12.

PMID:
8745635
31.

An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i blood group specificity on normal human B cells.

Grillot-Courvalin C, Brouet JC, Piller F, Rassenti LZ, Labaume S, Silverman GJ, Silberstein L, Kipps TJ.

Eur J Immunol. 1992 Jul;22(7):1781-8.

PMID:
1623923
33.

Early biochemical events after MHC class II-mediated signaling on human B lymphocytes.

Mooney NA, Grillot-Courvalin C, Hivroz C, Ju LY, Charron D.

J Immunol. 1990 Oct 1;145(7):2070-6.

PMID:
2398273
35.

Lymphocyte activation via MHC class II antigens.

Mooney NA, Ziai-Talebian S, Hivroz C, Miglierina R, Grillot-Courvalin C, Charron D.

Nouv Rev Fr Hematol. 1990;32(1):53-7.

PMID:
2349082
36.

Signal transduction via MHC class II antigens on B lymphocytes.

Mooney N, Hivroz C, Ziai-Talebian S, Grillot-Courvalin C, Charron D.

J Immunogenet. 1989 Aug-Oct;16(4-5):273-81.

PMID:
2639902
37.

A role for MHC class II antigens in B-cell activation.

Mooney N, Grillot-Courvalin C, Hivroz C, Charron D.

J Autoimmun. 1989 Jun;2 Suppl:215-23.

PMID:
2789060
38.

Regulation by interleukin 2 of CD23 expression of leukemic and normal B cells: comparison with interleukin 4.

Hivroz C, Vallé A, Brouet JC, Banchereau J, Grillot-Courvalin C.

Eur J Immunol. 1989 Jun;19(6):1025-30.

PMID:
2526738
39.

Cross-linking of membrane IgM on B CLL cells: dissociation between intracellular free Ca2+ mobilization and cell proliferation.

Hivroz C, Grillot-Courvalin C, Labaume S, Miglierina R, Brouet JC.

Eur J Immunol. 1988 Nov;18(11):1811-7.

PMID:
3144454
40.

Cross-linking of membrane IgM on B CLL cells.

Grillot-Courvalin C, Hivroz C, Brouet JC.

Nouv Rev Fr Hematol. 1988;30(5-6):301-4.

PMID:
3146745
41.
42.

Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor or interleukin 2.

Hivroz C, Grillot-Courvalin C, Brouet JC, Seligmann M.

Eur J Immunol. 1986 Aug;16(8):1001-4.

PMID:
3488907
43.

Differentiation by interleukin 2 of a subpopulation of human B cells.

Grillot-Courvalin C, Labaume S, Brouet JC.

Scand J Immunol. 1986 Jun;23(6):679-84.

PMID:
3487111
44.

Interleukin 2-induced proliferation of leukemic human B cells.

Lantz O, Grillot-Courvalin C, Schmitt C, Fermand JP, Brouet JC.

J Exp Med. 1985 May 1;161(5):1225-30.

45.

Induction of suppressive cells within the T4 subset by a human T-T hybridoma-produced factor.

Grillot-Courvalin C, Labaume S, Brouet JC.

Eur J Immunol. 1983 Dec;13(12):1013-6.

PMID:
6229406
46.

Functional T4 helper cells in patient with HTLV related Sézary syndrome.

Grillot-Courvalin C, Brouet JC, Chermann JC.

Lancet. 1983 Sep 10;2(8350):619-20. No abstract available.

PMID:
6136761
47.

Characterization of a suppressive factor produced by a human T hybridoma.

Grillot-Courvalin C, Dellagi K, Chevalier A, Brouet JC.

J Immunol. 1982 Sep;129(3):1008-11.

PMID:
6980912
48.

Establishment of a human T-cell hybrid line with suppressive activity.

Grillot-Courvalin C, Brouet JC, Berger R, Bernheim A.

Nature. 1981 Aug 27;292(5826):844-5. No abstract available.

PMID:
6973698
49.

Human antibody reacts with a B-cell subset in man to induce B-cell differentiation.

Brouet JC, Grillot-Courvalin C, Seligmann M.

Nature. 1980 Feb 14;283(5748):668-9. No abstract available.

PMID:
6965521
50.

Antigenic requirements for the generation of secondary cytotoxicity.

Grillot-Courvalin C, Alter BJ, Bach FH.

J Immunol. 1977 Oct;119(4):1253-9.

PMID:
142790

Supplemental Content

Loading ...
Support Center